- Home
- AUST vs CASI Comparison
AUST vs CASI Comparison
Compare AUST & CASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AUST | CASI |
|---|---|---|
| Founded | 2020 | 1991 |
| Country | Canada | China |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.0M | 24.9M |
| IPO Year | 2022 | 1996 |
Fundamental Metrics
Financial Performance| Metric | AUST | CASI |
|---|---|---|
| Price | $1.67 | $0.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 121.4K | 31.4K |
| Earning Date | 02-26-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $26,846,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 21.72 |
| 52 Week Low | $1.05 | $0.75 |
| 52 Week High | $2.94 | $3.29 |
Technical Indicators
Market Signals| Indicator | AUST | CASI |
|---|---|---|
| Relative Strength Index (RSI) | 48.07 | 42.70 |
| Support Level | $1.46 | $0.81 |
| Resistance Level | $1.70 | $0.91 |
| Average True Range (ATR) | 0.16 | 0.07 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 40.38 | 55.56 |
Price Performance
Historical ComparisonAbout AUST Austin Gold Corp.
Austin Gold Corp is focused on the acquisition, exploration and evaluation of mineral resource properties in the western United States of America (USA). Exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek in Humboldt County, Lone Mountain and Miller in Elko County, and Stockade Mountain (Oregon).
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.